ResMed (RMD) 10-Q 27 Oct 15 2016 Q1 Quarterly report Financial data

Document And Entity Information

Document And Entity Information - shares	3 Months Ended
	Sep. 30, 2015	Oct. 20, 2015
Document And Entity Information [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Sep. 30, 2015
Document Fiscal Year Focus	2,016
Document Fiscal Period Focus	Q1
Trading Symbol	rmd
Entity Registrant Name	RESMED INC
Entity Central Index Key	943,819
Current Fiscal Year End Date	--06-30
Entity Filer Category	Large Accelerated Filer
Entity Common Stock, Shares Outstanding		139,649,869

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($) $ in Thousands	Sep. 30, 2015	Jun. 30, 2015
Current assets:
Cash and cash equivalents	$ 822,053	$ 717,249
Accounts receivable, net of allowance for doubtful accounts of $13,394 and $12,276 at September 30, 2015 and June 30, 2015, respectively	327,168	362,568
Inventories (note 3)	258,609	246,859
Deferred income taxes	41,494	36,338
Prepaid expenses and other current assets	83,476	81,168
Total current assets	1,532,800	1,444,182
Non-current assets:
Property, plant and equipment, net (note 4)	368,984	387,758
Goodwill and other intangible assets, net (note 6)	305,418	311,403
Deferred income taxes	11,990	12,528
Other assets	35,487	28,389
Total non-current assets	721,879	740,078
Total assets	2,254,679	2,184,260
Current liabilities:
Accounts payable	77,482	81,112
Accrued expenses	117,651	132,976
Deferred revenue	34,848	36,097
Income taxes payable	26,550	16,278
Deferred income taxes	776	796
Total current liabilities	257,307	267,259
Non-current liabilities:
Deferred income taxes	7,968	8,062
Deferred revenue	23,446	19,284
Long-term debt (note 7)	500,587	300,594
Other long-term liabilities	2,804
Income taxes payable	1,754	1,754
Total non-current liabilities	536,559	329,694
Total liabilities	$ 793,866	$ 596,953
Commitments and contingencies (note 12)
Stockholders' equity: (note 10)
Preferred stock, $0.01 par value, 2,000,000 shares authorized; none issued
Common stock, $0.004 par value, 350,000,000 shares authorized; 179,925,750 issued and 139,539,516 outstanding at September 30, 2015 and 179,660,939 issued and 140,474,705 outstanding at June 30, 2015	$ 558	$ 562
Additional paid-in capital	1,248,077	1,228,795
Retained earnings	2,014,344	1,976,020
Treasury stock, at cost, 40,386,234 shares at September 30, 2015, and 39,186,234 shares at June 30, 2015	(1,506,542)	(1,444,554)
Accumulated other comprehensive (loss) income	(295,624)	(173,516)
Total stockholders' equity	1,460,813	1,587,307
Total liabilities and stockholders' equity	$ 2,254,679	$ 2,184,260

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parenthetical) - USD ($) $ in Thousands	Sep. 30, 2015	Jun. 30, 2015
Consolidated Balance Sheets [Abstract]
Accounts receivable, allowance for doubtful accounts	$ 13,394	$ 12,276
Preferred stock, par value	$ 0.01	$ 0.01
Preferred stock, shares authorized	2,000,000	2,000,000
Preferred stock, shares issued	0	0
Common stock, par value	$ 0.004	$ 0.004
Common stock, shares authorized	350,000,000	350,000,000
Common stock, shares issued	179,925,750	179,660,939
Common stock, shares outstanding	139,539,516	140,474,705
Treasury stock, shares held	40,386,234	39,186,234

Consolidated Statements Of Inco

Consolidated Statements Of Income - USD ($) shares in Thousands, $ in Thousands	3 Months Ended
	Sep. 30, 2015	Sep. 30, 2014
Consolidated Statements Of Income [Abstract]
Net revenue	$ 411,647	$ 380,399
Cost of sales (excluding amortization of acquired intangible assets)	173,028	143,086
Gross profit	238,619	237,313
Operating expenses:
Selling, general and administrative	111,095	110,520
Research and development	27,192	30,024
Amortization of acquired intangible assets	2,307	2,094
Total operating expenses	140,594	142,638
Income from operations	98,025	94,675
Other income, net:
Interest income, net	3,422	5,584
Other, net	(2,003)	1,671
Total other income, net	1,419	7,255
Income before income taxes	99,444	101,930
Income taxes	19,041	18,670
Net income	$ 80,403	$ 83,260
Basic earnings per share	$ 0.57	$ 0.59
Diluted earnings per share (note 2)	0.57	0.58
Dividend declared per share	$ 0.30	$ 0.28
Basic shares outstanding (000's)	140,309	140,127
Diluted shares outstanding (000's)	141,946	142,683

Consolidated Statements Of Comp

Consolidated Statements Of Comprehensive Income - USD ($) $ in Thousands	3 Months Ended
	Sep. 30, 2015	Sep. 30, 2014
Consolidated Statements Of Comprehensive Income [Abstract]
Net income	$ 80,403	$ 83,260
Other comprehensive income:
Foreign currency translation (loss) gain adjustments	(122,108)	(125,108)
Comprehensive (loss) income	$ (41,705)	$ (41,848)

Consolidated Statements Of Cash

Consolidated Statements Of Cash Flows - USD ($) $ in Thousands	3 Months Ended
	Sep. 30, 2015	Sep. 30, 2014
Cash flows from operating activities:
Net income	$ 80,403	$ 83,260
Adjustment to reconcile net income to net cash provided by operating activities:
Depreciation and amortization	18,403	18,582
Gain on divestment of business		(709)
Stock-based compensation costs	12,383	11,367
Excess tax benefit from stock-based compensation arrangements	(2,536)	(2,575)
Changes in operating assets and liabilities, net of effect of acquisitions:
Accounts receivable, net	30,498	20,804
Inventories, net	(17,194)	(37,897)
Prepaid expenses, net deferred income taxes and other current assets	(3,526)	(15,168)
Accounts payable, accrued expenses and other liabilities	3,641	8,872
Net cash provided by operating activities	122,072	86,536
Cash flows from investing activities:
Purchases of property, plant and equipment	(16,403)	(20,681)
Patent registration costs	(2,423)	(2,366)
Business acquisitions, net of cash acquired		(7,318)
Investments in cost-method investments	(4,582)	(500)
Proceeds from divestiture of business		468
Payments on maturity of foreign currency contracts	(39,341)	(11,206)
Net cash provided by (used in) investing activities	(62,749)	(41,603)
Cash flows from financing activities:
Proceeds from issuance of common stock, net	4,352	4,930
Excess tax benefit from stock-based compensation arrangements	2,536	2,575
Purchases of treasury stock	(57,857)	(46,803)
Payment of business combination contingent consideration		(458)
Proceeds from borrowings, net of borrowing costs	200,000	75,000
Repayment of borrowings	(8)	(10)
Dividends paid	(42,079)	(39,199)
Net cash provided by (used in) financing activities	106,944	(3,965)
Effect of exchange rate changes on cash	(61,463)	(65,004)
Net (decrease) increase in cash and cash equivalents	104,804	(24,036)
Cash and cash equivalents at beginning of period	717,249	905,730
Cash and cash equivalents at end of period	822,053	881,694
Supplemental disclosure of cash flow information:
Income taxes paid, net of refunds	18,118	14,373
Interest paid	$ 1,247	1,233
Fair value of assets acquired, excluding cash		7,342
Liabilities assumed		(3,168)
Goodwill on acquisition		6,454
Deferred payments		(2,405)
Fair value of contingent consideration		(905)
Total purchase price, excluding contingent consideration		$ 7,318

Summary Of Significant Accounti

Summary Of Significant Accounting Policies	3 Months Ended
	Sep. 30, 2015
Summary Of Significant Accounting Policies [Abstract]
Summary Of Significant Accounting Policies	(1) Summary of Significant Accounting Policies Organization and Basis of Presentation ResMed Inc. (referred to herein as “we”, “us”, “our” or the “Company”) is a Delaware corporation formed in March 1994 as a holding company for the ResMed Group. Through our subsidiaries, we design, manufacture and market equipment for the diagnosis and treatment of sleep-disordered breathing and other respiratory disorders, including obstructive sleep apnea. Our manufacturing operations are located in Australia, Singapore, France, Germany, Malaysia and the United States. Major distribution and sales sites are located in the United States, Germany, France, the United Kingdom, Switzerland, Australia, Japan, Norway and Sweden. The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles (“U.S. GAAP”) for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X of the U.S. Securities and Exchange Commission (“SEC”). Accordingly, they do not include all of the information and footnotes required by U.S. GAAP for complete financial statements. In the opinion of management, all necessary adjustments, which consisted only of normal recurring items, have been included in the accompanying financial statements to present fairly the results of the interim periods. The results of operations for the interim periods presented are not necessarily indicative of the results that may be expected for the year ending June 30, 2016. The condensed consolidated financial statements for the three months ended September 30, 2015 and 2014 are unaudited and should be read in conjunction with the consolidated financial statements and notes thereto included in our Form 10-K for the year ended June 30, 2015. New Accounting Pronouncements In May, 2014, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) No. 2014-09, “Revenue from Contracts with Customers”, which requires an entity to recognize the amount of revenue to which it expects to be entitled for the transfer of promised goods or services to customers. The ASU will replace most existing revenue recognition guidance in U.S. GAAP when it becomes effective. The new standard is effective for the Company beginning in the first quarter of fiscal year 2019. Early application is not permitted. We are currently assessing the impact of the adoption of ASU 2014-09 on our financial condition, results of operations and cash flows. In April, 2015, the FASB issued ASU No. 2015-03, "Simplifying the Presentation of Debt Issuance Costs". ASU 2015-03 will more closely align the presentation of debt issuance costs under U.S. GAAP with the presentation under comparable International Financial Reporting Standards (IFRS) by requiring that debt issuance costs be presented on the balance sheet as a direct deduction from the carrying amount of the related debt liability. The new standard is effective for us beginning in the first quarter of fiscal 2017. We do not expect this updated standard to have a material impact on our consolidated financial statements and related disclosures. In July 2015, the FASB issued ASU No. 2015-11, “Simplifying the Measurement of Inventory” which requires an entity to measure inventory within the scope of this ASU at the lower of cost and net realizable value. Net realizable value is the estimated selling prices in the ordinary course of business, less reasonably predictable costs of completion, disposal, and transportation. The amendments in this guidance more closely align the measurement of inventory in GAAP with the measurement of inventory in IFRS. The new standard is effective for us beginning in the first quarter of fiscal 2018. We do not expect this updated standard to have a material impact on our consolidated financial statements and related disclosures.

Earnings Per Share

Earnings Per Share	3 Months Ended
	Sep. 30, 2015
Earnings Per Share [Abstract]
Earnings Per Share	(2) Earnings Per Share Basic earnings per share is computed by dividing the net income available to common stockholders by the weighted average number of shares of common stock outstanding. For purposes of calculating diluted earnings per share, the denominator includes both the weighted average number of shares of common stock outstanding and the number of dilutive common stock equivalents such as stock options and restricted stock units. Stock options and restricted stock units of 98,697 and 154,551 , for the three months ended September 30, 2015 and 2014, respectively, were not included in the computation of diluted earnings per share as the effect would have been anti-dilutive. Basic and diluted earnings per share for the three months ended September 30, 2015 and 2014 are calculated as follows (in thousands except per share data): Three Months Ended September 30, 2015 2014 Numerator: Net Income $ $ Denominator: Basic weighted-average common shares outstanding Effect of dilutive securities: Stock options and restricted stock units Diluted weighted average shares Basic earnings per share $ $ Diluted earnings per share $ $

Inventories

Inventories	3 Months Ended
	Sep. 30, 2015
Inventories [Abstract]
Inventories	(3) Inventories Inventories were comprised of the following at September 30, 2015 and June 30, 2015 (in thousands): September 30, 2015 June 30, 2015 Raw materials $ $ Work in progress Finished goods Total inventories $ $

Property, Plant And Equipment

Property, Plant And Equipment	3 Months Ended
	Sep. 30, 2015
Property, Plant And Equipment, Net [Abstract]
Property, Plant And Equipment	(4) Property, Plant and Equipment Property, plant and equipment were comprised of the following as of September 30, 2015 and June 30, 2015 (in thousands): September 30, 2015 June 30, 2015 Machinery and equipment $ $ Computer equipment Furniture and fixtures Vehicles Clinical, demonstration and rental equipment Leasehold improvements Land Buildings Accumulated depreciation and amortization Property, plant and equipment, net $ $

Cost-Method Investments

Cost-Method Investments	3 Months Ended
	Sep. 30, 2015
Cost-Method Investments [Abstract]
Cost-Method Investments	(5) Cost-Method Investments The aggregate carrying amount of our cost-method investments at September 30, 2015 and June 30, 2015, was $30.2 million and $ 25.6 million, respectively, and is included in the non-current balance of other assets on the condensed consolidated balance sheets. We periodically evaluate the carrying value of our cost-method investments, when events and circumstances indicate that the carrying amount of an asset may not be recovered. We estimate the fair value of our cost-method investments to assess whether impairment losses shall be recorded using Level 3 inputs. These investments include our holdings in privately held service and research companies that are not exchange traded and therefore not supported with observable market prices. However, these investments are valued by reference to their net asset values that can be market supported and unobservable inputs including future cash flows. During the three months ended September 30, 2015 and 2014, we did not recognize any impairment losses related to our cost-method investments. We have determined that the fair value of our investments exceed their carrying values. The following table shows a reconciliation of the changes in our cost-method investments during the three months ended September 30, 2015 and 2014 (in thousands): Three Months Ended September 30, 2015 2014 Balance at the beginning of the period $ $ Investments Balance at the end of the period $ $

Goodwill And Other Intangible A

Goodwill And Other Intangible Assets, Net	3 Months Ended
	Sep. 30, 2015
Goodwill And Other Intangible Assets, Net [Abstract]
Goodwill And Other Intangible Assets, Net	(6) Goodwill and Other Intangible Assets, net Goodwill Changes in the carrying amount of goodwill for the three months ended September 30, 2015, and 2014 were as follows (in thousands): Three Months Ended September 30, 2015 2014 Balance at the beginning of the period $ $ Business acquisition - Foreign currency translation adjustments Balance at the end of the period $ $ Other Intangible Assets Other intangible assets were comprised of the following as of September 30, 2015, and June 30, 2015 (in thousands): September 30, 2015 June 30, 2015 Developed/core product technology $ $ Accumulated amortization Developed/core product technology, net Trade names Accumulated amortization Trade names, net Non-compete agreements Accumulated amortization Non compete agreements, net - Customer relationships Accumulated amortization Customer relationships, net Patents Accumulated amortization Patents, net Total other intangibles, net $ $ Intangible assets consist of patents, customer relationships, trade names, non-compete agreements and developed/core product technology. We amortize intangible assets over the estimated useful life of the assets, generally between two and nine years. There are no expected residual values related to these intangible assets.

Long-Term Debt

Long-Term Debt	3 Months Ended
	Sep. 30, 2015
Long-Term Debt [Abstract]
Long-Term Debt	(7) Long-Term Debt Long-term debt at September 30, 2015 and June 30, 2015 consisted of the following (in thousands): September 30, 2015 June 30, 2015 Current long-term debt $ - $ - Non-current long-term debt Total long-term debt $ $ Credit Facility On October 31, 2013, we entered into a credit agreement, as borrower, with lenders, including Union Bank, N.A., as administrative agent, joint lead arranger, swing line lender and letters of credit issuer, and HSBC Bank USA, National Association, as syndication agent and joint lead arranger. Our obligations under the credit agreement are guaranteed by ResMed Corp. and ResMed Motor Technologies Inc., two of our U.S. subsidiaries. The credit agreement provides a $700 million senior unsecured five -year revolving credit facility, with an uncommitted option to increase the credit facility by an additional $300 million. The credit facility also includes a $25 million sublimit for letters of credit. The credit facility terminates on October 31, 2018 , when all unpaid principal and interest under the loans must be repaid. The outstanding principal amount due under the credit facility will bear interest at a rate equal to LIBOR plus 1.0% to 2.0% (depending on the then-applicable leverage ratio). At September 30, 2015, the interest rate that was being charged on the outstanding principal amount was 1.2% . An applicable commitment fee of 0.15% to 0.25% (depending on the then-applicable leverage ratio) applies on the unused portion of the credit facility. When we entered into the credit agreement, we used a portion of the proceeds from the initial funding of the credit facility to repay the outstanding balance under our previous revolving credit facility with Union Bank, N.A and other lenders. On that repayment, the previous credit agreement, dated as of February 10, 2011, between us and lenders (including Union Bank, N.A., as administrative agent, swing line lender and letter of credit issuer, HSBC Bank USA, National Association, as syndication agent and Union Bank, N.A., HSBC Bank USA, National Association, Commonwealth Bank of Australia and Wells Fargo Bank), was terminated and the commitments under the previous credit agreement were also terminated. Our obligations under the current credit agreement are unsecured but are guaranteed by two of our U.S. subsidiaries. The credit agreement contains customary covenants, including certain financial covenants and an obligation that we maintain certain financial ratios, including a maximum leverage ratio of funded debt to EBITDA (as defined in the credit agreement) and an interest coverage ratio. The entire principal amount of the credit facility and any accrued but unpaid interest may be declared immediately due and payable if an event of default occurs, as defined in the credit agreement. Events of default under the credit agreement include failure to make payments when due, the occurrence of a default in the performance of any covenants in the credit agreement or related documents, or certain changes of control of ResMed Inc., ResMed Corp., ResMed Motor Technologies Inc., ResMed Limited, ResMed Holdings Ltd/LLC or ResMed EAP Holdings LLC. At September 30, 2015, there was $ 500.0 million outstanding under the credit agreement.

Product Warranties

Product Warranties	3 Months Ended
	Sep. 30, 2015
Product Warranties [Abstract]
Product Warranties	(8) Product Warranties Changes in the liability for warranty costs, which is included in accrued expenses in our condensed consolidated balance sheets, for the three months ended September 30, 2015 and 2014 are as follows (in thousands): Three Months Ended September 30, 2015 2014 Balance at the beginning of the period $ $ Warranty accruals for the period Warranty costs incurred for the period Foreign currency translation adjustments Balance at the end of the period $ $

Stock-Based Employee Compensati

Stock-Based Employee Compensation	3 Months Ended
	Sep. 30, 2015
Stock-Based Employee Compensation [Abstract]
Stock-Based Employee Compensation	(9) Stock-Based Employee Compensation We measure the compensation expense of all stock-based awards at fair value on the grant date. We estimate the fair value of stock options and purchase rights granted under the employee stock purchase plan (the “ESPP”) using the Black-Scholes valuation model. The fair value of restricted stock units is equal to the market value of the underlying shares as determined at the grant date less the fair value of dividends that holders are not entitled to, during the vesting period. The fair value of performance restricted stock units which contain a market condition, are estimated using a Monte-Carlo simulation model. We recognize the fair value as compensation expense using the straight-line method over the service period for awards expected to vest. We estimate the fair value of purchase rights granted under the ESPP using the following assumptions: Three Months Ended September 30, 2015 2014 Stock options: Weighted average grant date fair value $ - $ - Weighted average risk-free interest rate - - Expected option life in years - - Dividend yield - - Expected volatility - - ESPP purchase rights: Weighted average risk-free interest rate 0.1% 0.1% Expected option life in years 6 months 6 months Dividend yield 1.73% 2.00% Expected volatility 26% 24%

Stockholders' Equity

Stockholders' Equity	3 Months Ended
	Sep. 30, 2015
Stockholders' Equity [Abstract]
Stockholders' Equity	(10) Stockholders’ Equity Common Stock. During the three months ended September 30, 2015 and 2014 we repurchased 1.2 million and 0.8 million shares at a cost of $62.0 million and $42.9 million, respectively. Since the inception of our share repurchase programs and through September 30, 2015, we have repurchased a total of 4 0.4 million shares at a cost of $1.5 billion. Shares that are repurchased are classified as treasury stock pending future use and reduce the number of shares outstanding used in calculating earnings per share. At September 30, 2015, 14.3 million additional shares can be repurchased under the approved share repurchase program. Preferred Stock. In April 1997, the board of directors designated 2,000,000 shares of our $0.01 par value preferred stock as Series A Junior Participating Preferred Stock. No shares were issued or outstanding at September 30, 2015 and June 30, 2015 . Stock Options and Restricted Stock Units. We have granted stock options and restricted stock units to personnel, including officers and directors, in accordance with the ResMed Inc. 2009 Incentive Award Plan (the “2009 Plan”). These options and restricted stock units have expiration dates of seven years from the date of grant and vest over one to four years. We have granted the options with an exercise price equal to the market value as determined at the date of grant. The maximum number of shares of our common stock authorized for issuance under the 2009 Plan is 43.7 million shares. The number of securities remaining available for future issuance under the 2009 Plan at September 30, 2015 is 13.8 million. The number of shares of our common stock available for issuance under the 2009 Plan will be reduced by (i) 2.8 shares for each one share of common stock delivered in settlement of any “full-value award,” which is any award other than a stock option, stock appreciation right or other award for which the holder pays the intrinsic value and (ii) one share for each share of common stock delivered in settlement of all other awards. The maximum number of shares, that may be subject to awards granted under the 2009 Plan to any individual during any calendar year, may not exceed 3 million shares of our common stock (except in a participant’s initial year of hiring, when up to 4.5 million shares of our common stock may be granted). At September 30, 2015, there were $ 57.1 million in unrecognized compensation costs related to unvested stock-based compensation arrangements. This is expected to be recognized over a weighted average period of 2.0 years. The aggregate intrinsic value of the stock-based compensation arrangements outstanding and exercisable at September 30, 2015 was $ 168.5 million and $ 46.3 million, respectively. The aggregate intrinsic value of the options exercised during the three months ended September 30, 2015 and 2014, was $ 8.9 million and $ 9.7 million, respectively. The following table summarizes option activity during the three months ended September 30, 2015: Weighted Average Exercise Price Weighted Average Remaining Contractual Term in Years Outstanding at beginning of period $ 2.5 Granted - - Exercised Forfeited Outstanding at end of period $ 2.5 Exercise price of granted options $ - Options exercisable at end of period $ The following table summarizes the activity of restricted stock units during the three months ended September 30, 2015: Weighted Average Grant-Date Fair Value Weighted Average Remaining Contractual Term in Years Outstanding at beginning of period $ 1.2 Granted Vested Forfeited Outstanding at end of period $ 0.9 Employee Stock Purchase Plan (the “ESPP”). Under the ESPP, we offer participants the right to purchase shares of our common stock at a discount during successive offering periods. Each offering period under the ESPP will be for a period of time determined by the board of directors’ compensation committee of no less than 3 months and no more than 27 months. The purchase price for our common stock under the ESPP will be the lower of 85 % of the fair market value of our common stock on the date of grant or 85 % of the fair market value of our common stock on the date of purchase. An individual participant cannot subscribe for more than $ 25,000 in common stock during any calendar year. At September 30, 2015, the number of shares remaining available for future issuance under the ESPP is 1. 5 million shares.

Fair Value Measurements

Fair Value Measurements	3 Months Ended
	Sep. 30, 2015
Fair Value Measurements [Abstract]
Fair Value Measurements	(11) Fair Value Measurements In determining the fair value measurements of our financial assets and liabilities, we consider the principal and most advantageous market in which we transact and consider assumptions that market participants would use when pricing the financial asset or liability. We maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. The hierarchies of inputs are as follows: · Level 1: Input prices quoted in an active market for identical financial assets or liabilities; · Level 2: Inputs other than prices quoted in Level 1, such as prices quoted for similar financial assets and liabilities in active markets, prices for identical assets and liabilities in markets that are not active or other inputs that are observable or can be corroborated by observable market data; and · Level 3: Input prices quoted that are significant to the fair value of the financial assets or liabilities which are not observable nor supported by an active market. The following table summarizes our financial assets and liabilities, as at September 30, 2015 and June 30, 2015, using the valuation input hierarchy (in thousands): Level 1 Level 2 Level 3 Total Balances at September 30, 2015 Foreign currency hedging instruments, net $ - $ $ - $ Business acquisition contingent consideration $ - $ - $ $ Balances at June 30, 2015 Foreign currency hedging instruments, net $ - $ $ - $ Business acquisition contingent consideration $ - $ - $ $ We determine the fair value of our financial assets and liabilities as follows: · Foreign currency hedging instruments – These financial instruments are valued using third-party valuation models based on market observable inputs, including interest rate curves, on-market spot currency prices, volatilities and credit risk. · Contingent consideration – These liabilities include the fair value estimates of additional future payments that may be required for some of our previous business acquisitions based on the achievement of certain performance milestones. Each potential future payment is valued using the estimated probability of achieving each milestone, which is then discounted to present value. The following is a reconciliation of changes in the fair value of contingent consideration for the three months ended September 30, 2015 and 2014 (in thousands): Three Months Ended September 30, 2015 2014 Balance at the beginning of the period $ $ Acquisition date fair value of contingent consideration - Changes in fair value included in operating income - Payments - Foreign currency translation adjustments Balance at the end of the period $ $ We did not have any significant non-financial assets or liabilities measured at fair value on September 30, 2015 or June 30, 2015.

Legal Actions And Contingencies

Legal Actions And Contingencies	3 Months Ended
	Sep. 30, 2015
Legal Actions And Contingencies [Abstract]
Legal Actions And Contingencies	(12) Legal Actions and Contingencies Litigation In the normal course of business, we are subject to routine litigation incidental to our business. While the results of this litigation cannot be predicted with certainty, we believe that their final outcome will not, individually or in aggregate, have a material adverse effect on our consolidated financial statements taken as a whole. Obligations Under Recourse Provisions We use independent leasing companies to provide financing to certain customers for the purchase of our products. In some cases, we are liable in the event of a customer default, to the leasing companies, within certain limits, for unpaid installment receivables transferred to the leasing companies. The gross amount of receivables sold with recourse during the three months ended September 30, 2015 and 2014, amounted to $16.1 million and $2.0 million, respectively. The maximum potential amount of contingent liability under these arrangements at September 30, 2015 and June 30, 2015 were $9.1 million, and $7.2 million, respectively. The recourse liability recognized by us at September 30, 2015 and June 30, 2015, in relation to these arrangements was $0.5 million and $0.5 million, respectively.

Derivative Instruments And Hedg

Derivative Instruments And Hedging Activities	3 Months Ended
	Sep. 30, 2015
Derivative Instruments And Hedging Activities [Abstract]
Derivative Instruments And Hedging Activities	(13) Derivative Instruments and Hedging Activities We transact business in various foreign currencies, including a number of major European currencies as well as the Australian and Singapore dollars. We have significant foreign currency exposure through both our Australian and Singaporean manufacturing activities, and international sales operations. We have established a foreign currency hedging program using purchased currency options and forward contracts to hedge foreign-currency-denominated financial assets, liabilities and manufacturing cash flows. The terms of such foreign currency hedging contracts generally do not exceed three years. The goal of this hedging program is to economically manage the financial impact of foreign currency exposures denominated mainly in Euros, and Australian and Singapore dollars. Under this program, increases or decreases in our foreign currency denominated financial assets, liabilities, and firm commitments are partially offset by gains and losses on the hedging instruments. We do not designate these foreign currency contracts as hedges. We have determined our hedge program to be a non-effective hedge as defined under the FASB issued authoritative guidance. All movements in the fair value of the foreign currency instruments are recorded within other income, net in our condensed consolidated statements of income. We do not enter into financial instruments for trading or speculative purposes. We held foreign currency instruments with notional amounts totaling $ 620.2 million and $ 576.5 million at September 30, 2015 and June 30, 2015, respectively, to hedge foreign currency fluctuations. These contracts mature at various dates prior to September 30, 2018. The following table summarizes the amount and location of our derivative financial instruments as of September 30, 2015 and June 30, 2015 (in thousands): September 30, 2015 June 30, 2015 Balance Sheet Caption Foreign currency hedging instruments $ $ Other assets - current Foreign currency hedging instruments Other assets - non current Foreign currency hedging instruments Accrued expenses Foreign currency hedging instruments - Other long-term liabilities $ $ The following table summarizes the amount and location of gains (losses) associated with our derivative financial instruments for the three months ended September 30, 2015 and September 30, 2014, respectively (in thousands): Gain /(Loss) Recognized Income Statement Caption Three Months Ended September 30, 2015 2014 Foreign currency hedging instruments $ $ Other, net Other foreign-currency-denominated transactions Other, net $ $ We are exposed to credit-related losses in the event of non-performance by counter parties to financial instruments. We minimize counterparty credit risk by entering into derivative transactions with major financial institutions and we do not expect material losses as a result of default by our counterparties.

Subsequent Events

Subsequent Events	3 Months Ended
	Sep. 30, 2015
Subsequent Events [Abstract]
Subsequent Events	(14) Subsequent Events On October 2, 2015 we completed the acquisition of 100% of the shares in Curative Medical Technology Inc., a leading provider of non-invasive ventilation and sleep-disordered breathing medical devices and accessories in China. This acquisition will be accounted for as a business combination using purchase accounting and will be included in our condensed consolidated financial statements from the acquisition date. The acquisition is not considered a material business combination and was funded through cash on-hand. We have not incurred any material acquisition-related costs. The preliminary purchase price allocation will be completed during the quarter ending December 31, 2015.

Summary Of Significant Accoun21

Summary Of Significant Accounting Policies (Policy)	3 Months Ended
	Sep. 30, 2015
Summary Of Significant Accounting Policies [Abstract]
Organization And Basis Of Presentation	Organization and Basis of Presentation ResMed Inc. (referred to herein as “we”, “us”, “our” or the “Company”) is a Delaware corporation formed in March 1994 as a holding company for the ResMed Group. Through our subsidiaries, we design, manufacture and market equipment for the diagnosis and treatment of sleep-disordered breathing and other respiratory disorders, including obstructive sleep apnea. Our manufacturing operations are located in Australia, Singapore, France, Germany, Malaysia and the United States. Major distribution and sales sites are located in the United States, Germany, France, the United Kingdom, Switzerland, Australia, Japan, Norway and Sweden. The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles (“U.S. GAAP”) for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X of the U.S. Securities and Exchange Commission (“SEC”). Accordingly, they do not include all of the information and footnotes required by U.S. GAAP for complete financial statements. In the opinion of management, all necessary adjustments, which consisted only of normal recurring items, have been included in the accompanying financial statements to present fairly the results of the interim periods. The results of operations for the interim periods presented are not necessarily indicative of the results that may be expected for the year ending June 30, 2016. The condensed consolidated financial statements for the three months ended September 30, 2015 and 2014 are unaudited and should be read in conjunction with the consolidated financial statements and notes thereto included in our Form 10-K for the year ended June 30, 2015.
New Accounting Pronouncements	New Accounting Pronouncements In May, 2014, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) No. 2014-09, “Revenue from Contracts with Customers”, which requires an entity to recognize the amount of revenue to which it expects to be entitled for the transfer of promised goods or services to customers. The ASU will replace most existing revenue recognition guidance in U.S. GAAP when it becomes effective. The new standard is effective for the Company beginning in the first quarter of fiscal year 2019. Early application is not permitted. We are currently assessing the impact of the adoption of ASU 2014-09 on our financial condition, results of operations and cash flows. In April, 2015, the FASB issued ASU No. 2015-03, "Simplifying the Presentation of Debt Issuance Costs". ASU 2015-03 will more closely align the presentation of debt issuance costs under U.S. GAAP with the presentation under comparable International Financial Reporting Standards (IFRS) by requiring that debt issuance costs be presented on the balance sheet as a direct deduction from the carrying amount of the related debt liability. The new standard is effective for us beginning in the first quarter of fiscal 2017. We do not expect this updated standard to have a material impact on our consolidated financial statements and related disclosures. In July 2015, the FASB issued ASU No. 2015-11, “Simplifying the Measurement of Inventory” which requires an entity to measure inventory within the scope of this ASU at the lower of cost and net realizable value. Net realizable value is the estimated selling prices in the ordinary course of business, less reasonably predictable costs of completion, disposal, and transportation. The amendments in this guidance more closely align the measurement of inventory in GAAP with the measurement of inventory in IFRS. The new standard is effective for us beginning in the first quarter of fiscal 2018. We do not expect this updated standard to have a material impact on our consolidated financial statements and related disclosures.

Earnings Per Share (Tables)

Earnings Per Share (Tables)	3 Months Ended
	Sep. 30, 2015
Earnings Per Share [Abstract]
Schedule Of Basic And Diluted Earnings Per Share	Three Months Ended September 30, 2015 2014 Numerator: Net Income $ $ Denominator: Basic weighted-average common shares outstanding Effect of dilutive securities: Stock options and restricted stock units Diluted weighted average shares Basic earnings per share $ $ Diluted earnings per share $ $

Inventories (Tables)

Inventories (Tables)	3 Months Ended
	Sep. 30, 2015
Inventories [Abstract]
Schedule Of Inventories	September 30, 2015 June 30, 2015 Raw materials $ $ Work in progress Finished goods Total inventories $ $

Property, Plant And Equipment (

Property, Plant And Equipment (Tables)	3 Months Ended
	Sep. 30, 2015
Property, Plant And Equipment, Net [Abstract]
Components Of Property, Plant And Equipment	September 30, 2015 June 30, 2015 Machinery and equipment $ $ Computer equipment Furniture and fixtures Vehicles Clinical, demonstration and rental equipment Leasehold improvements Land Buildings Accumulated depreciation and amortization Property, plant and equipment, net $ $

Cost-Method Investments (Tables

Cost-Method Investments (Tables)	3 Months Ended
	Sep. 30, 2015
Cost-Method Investments [Abstract]
Schedule Of Reconciliation Of Changes In Cost-Method Investments	Three Months Ended September 30, 2015 2014 Balance at the beginning of the period $ $ Investments Balance at the end of the period $ $

Goodwill And Other Intangible26

Goodwill And Other Intangible Assets, Net (Tables)	3 Months Ended
	Sep. 30, 2015
Goodwill And Other Intangible Assets, Net [Abstract]
Schedule Of Changes In Carrying Amount Of Goodwill	Three Months Ended September 30, 2015 2014 Balance at the beginning of the period $ $ Business acquisition - Foreign currency translation adjustments Balance at the end of the period $ $
Schedule Of Other Intangible Assets	September 30, 2015 June 30, 2015 Developed/core product technology $ $ Accumulated amortization Developed/core product technology, net Trade names Accumulated amortization Trade names, net Non-compete agreements Accumulated amortization Non compete agreements, net - Customer relationships Accumulated amortization Customer relationships, net Patents Accumulated amortization Patents, net Total other intangibles, net $ $

Long-Term Debt (Tables)

Long-Term Debt (Tables)	3 Months Ended
	Sep. 30, 2015
Long-Term Debt [Abstract]
Schedule Of Long-Term Debt	September 30, 2015 June 30, 2015 Current long-term debt $ - $ - Non-current long-term debt Total long-term debt $ $

Product Warranties (Tables)

Product Warranties (Tables)	3 Months Ended
	Sep. 30, 2015
Product Warranties [Abstract]
Schedule Of Changes In Liability For Warranty Costs	Three Months Ended September 30, 2015 2014 Balance at the beginning of the period $ $ Warranty accruals for the period Warranty costs incurred for the period Foreign currency translation adjustments Balance at the end of the period $ $

Stock-Based Employee Compensa29

Stock-Based Employee Compensation (Tables)	3 Months Ended
	Sep. 30, 2015
Stock-Based Employee Compensation [Abstract]
Schedule Of Assumptions For Fair Value Of Stock Option Plans And Purchase Rights Granted	Three Months Ended September 30, 2015 2014 Stock options: Weighted average grant date fair value $ - $ - Weighted average risk-free interest rate - - Expected option life in years - - Dividend yield - - Expected volatility - - ESPP purchase rights: Weighted average risk-free interest rate 0.1% 0.1% Expected option life in years 6 months 6 months Dividend yield 1.73% 2.00% Expected volatility 26% 24%

Stockholders' Equity (Tables)

Stockholders' Equity (Tables)	3 Months Ended
	Sep. 30, 2015
Stockholders' Equity [Abstract]
Schedule Of Option Activity	Weighted Average Exercise Price Weighted Average Remaining Contractual Term in Years Outstanding at beginning of period $ 2.5 Granted - - Exercised Forfeited Outstanding at end of period $ 2.5 Exercise price of granted options $ - Options exercisable at end of period $
Schedule Of Activity Of Restricted Stock Units	Weighted Average Grant-Date Fair Value Weighted Average Remaining Contractual Term in Years Outstanding at beginning of period $ 1.2 Granted Vested Forfeited Outstanding at end of period $ 0.9

Fair Value Measurements (Tables

Fair Value Measurements (Tables)	3 Months Ended
	Sep. 30, 2015
Fair Value Measurements [Abstract]
Summary Of Financial Assets And Liabilities	Level 1 Level 2 Level 3 Total Balances at September 30, 2015 Foreign currency hedging instruments, net $ - $ $ - $ Business acquisition contingent consideration $ - $ - $ $ Balances at June 30, 2015 Foreign currency hedging instruments, net $ - $ $ - $ Business acquisition contingent consideration $ - $ - $ $
Reconciliation For Fair Value Measurements Using Significant Unobservable Inputs	Three Months Ended September 30, 2015 2014 Balance at the beginning of the period $ $ Acquisition date fair value of contingent consideration - Changes in fair value included in operating income - Payments - Foreign currency translation adjustments Balance at the end of the period $ $

Derivative Instruments And He32

Derivative Instruments And Hedging Activities (Tables)	3 Months Ended
	Sep. 30, 2015
Derivative Instruments And Hedging Activities [Abstract]
Summary Of Amount And Location Of Derivative Financial Instruments	September 30, 2015 June 30, 2015 Balance Sheet Caption Foreign currency hedging instruments $ $ Other assets - current Foreign currency hedging instruments Other assets - non current Foreign currency hedging instruments Accrued expenses Foreign currency hedging instruments - Other long-term liabilities $ $
Summary Of Gains (Losses) Associated With Derivative Financial Instruments	Gain /(Loss) Recognized Income Statement Caption Three Months Ended September 30, 2015 2014 Foreign currency hedging instruments $ $ Other, net Other foreign-currency-denominated transactions Other, net $ $

Earnings Per Share (Narrative)

Earnings Per Share (Narrative) (Details) - shares	3 Months Ended
	Sep. 30, 2015	Sep. 30, 2014
Earnings Per Share [Abstract]
Stock options not included in the computation of diluted earnings per share	98,697	154,551

Earnings Per Share (Schedule Of

Earnings Per Share (Schedule Of Basic And Diluted Earnings Per Share) (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	3 Months Ended
	Sep. 30, 2015	Sep. 30, 2014
Earnings Per Share [Abstract]
Net income	$ 80,403	$ 83,260
Basic weighted-average common shares outstanding	140,309	140,127
Stock options and restricted stock units	1,637	2,556
Diluted weighted average shares	141,946	142,683
Basic earnings per share	$ 0.57	$ 0.59
Diluted earnings per share	$ 0.57	$ 0.58

Inventories (Schedule Of Invent

Inventories (Schedule Of Inventories) (Details) - USD ($) $ in Thousands	Sep. 30, 2015	Jun. 30, 2015
Inventories [Abstract]
Raw materials	$ 75,490	$ 74,416
Work in progress	2,215	2,550
Finished goods	180,904	169,893
Total inventories	$ 258,609	$ 246,859

Property, Plant And Equipment,

Property, Plant And Equipment, Net (Details) - USD ($) $ in Thousands	Sep. 30, 2015	Jun. 30, 2015
Property, Plant and Equipment [Line Items]
Property, plant and equipment, gross	$ 745,480	$ 770,246
Accumulated depreciation and amortization	(376,496)	(382,488)
Property, plant and equipment, net	368,984	387,758
Machinery And Equipment [Member]
Property, Plant and Equipment [Line Items]
Property, plant and equipment, gross	188,059	198,047
Computer Equipment [Member]
Property, Plant and Equipment [Line Items]
Property, plant and equipment, gross	126,928	125,423
Furniture And Fixtures [Member]
Property, Plant and Equipment [Line Items]
Property, plant and equipment, gross	37,396	38,511
Vehicles [Member]
Property, Plant and Equipment [Line Items]
Property, plant and equipment, gross	5,680	5,371
Clinical, Demonstration And Rental Equipment [Member]
Property, Plant and Equipment [Line Items]
Property, plant and equipment, gross	81,174	80,911
Leasehold Improvements [Member]
Property, Plant and Equipment [Line Items]
Property, plant and equipment, gross	30,915	31,553
Land [Member]
Property, Plant and Equipment [Line Items]
Property, plant and equipment, gross	51,905	54,915
Buildings [Member]
Property, Plant and Equipment [Line Items]
Property, plant and equipment, gross	$ 223,423	$ 235,515

Cost-Method Investments (Narrat

Cost-Method Investments (Narrative) (Details) - USD ($) $ in Thousands	Sep. 30, 2015	Jun. 30, 2015	Sep. 30, 2014	Jun. 30, 2014
Cost-Method Investments [Abstract]
Aggregate carrying amount of cost-method investments	$ 30,182	$ 25,600	$ 15,350	$ 14,850

Cost-Method Investments (Schedu

Cost-Method Investments (Schedule Of Reconciliation Of Changes In Cost-Method Investments) (Details) - USD ($) $ in Thousands	3 Months Ended
	Sep. 30, 2015	Sep. 30, 2014
Cost-Method Investments [Abstract]
Balance at the beginning of the period	$ 25,600	$ 14,850
Investments	4,582	500
Balance at the end of the period	$ 30,182	$ 15,350

Goodwill And Other Intangible39

Goodwill And Other Intangible Assets, Net (Schedule Of Changes In Carrying Amount Of Goodwill) (Details) - USD ($) $ in Thousands	3 Months Ended
	Sep. 30, 2015	Sep. 30, 2014
Goodwill And Other Intangible Assets, Net [Abstract]
Balance at the beginning of the period	$ 264,261	$ 289,312
Business acquisition		6,454
Foreign currency translation adjustments	(1,443)	(18,502)
Balance at the end of the period	$ 262,818	$ 277,264

Goodwill And Other Intangible40

Goodwill And Other Intangible Assets, Net (Schedule Of Other Intangible Assets) (Details) - USD ($) $ in Thousands	3 Months Ended
	Sep. 30, 2015	Jun. 30, 2015
Finite-Lived Intangible Assets [Line Items]
Total other intangibles, net	$ 42,600	$ 47,142
Developed/Core Product Technology [Member]
Finite-Lived Intangible Assets [Line Items]
Other intangibles, gross	66,104	67,548
Accumulated amortization	(51,144)	(50,373)
Total other intangibles, net	14,960	17,175
Trade Names [Member]
Finite-Lived Intangible Assets [Line Items]
Other intangibles, gross	2,478	2,500
Accumulated amortization	(2,214)	(2,206)
Total other intangibles, net	264	294
Non Compete Agreements [Member]
Finite-Lived Intangible Assets [Line Items]
Other intangibles, gross	1,590	1,747
Accumulated amortization	(1,590)	(1,704)
Total other intangibles, net		43
Customer Relationships [Member]
Finite-Lived Intangible Assets [Line Items]
Other intangibles, gross	29,102	30,538
Accumulated amortization	(19,532)	(19,308)
Total other intangibles, net	9,570	11,230
Patents [Member]
Finite-Lived Intangible Assets [Line Items]
Other intangibles, gross	63,533	66,585
Accumulated amortization	(45,727)	(48,185)
Total other intangibles, net	$ 17,806	$ 18,400
Minimum [Member]
Finite-Lived Intangible Assets [Line Items]
Intangible assets, estimated useful life	2 years
Maximum [Member]
Finite-Lived Intangible Assets [Line Items]
Intangible assets, estimated useful life	9 years

Long-Term Debt (Narrative) (Det

Long-Term Debt (Narrative) (Details)	Oct. 31, 2013USD ($)entity	Sep. 30, 2015USD ($)
Line of Credit Facility [Line Items]
Amount outstanding under credit facility		$ 500,000,000
Union Bank, N.A. and HSBC Bank USA [Member]
Line of Credit Facility [Line Items]
Credit facility termination date		Oct. 31, 2018
Interest rate on outstanding principal amount		1.20%
Union Bank, N.A. and HSBC Bank USA [Member] | Revolving Credit Facility [Member]
Line of Credit Facility [Line Items]
Maximum borrowing capacity	$ 700,000,000
Credit facility term, years	5 years
Uncommitted option to increase credit facility	$ 300,000,000
Number of US guarantors | entity	2
Union Bank, N.A. and HSBC Bank USA [Member] | Letters Of Credit [Member]
Line of Credit Facility [Line Items]
Maximum borrowing capacity	$ 25,000,000
Minimum [Member] | Union Bank, N.A. and HSBC Bank USA [Member]
Line of Credit Facility [Line Items]
Commitment fees percentage rate on unused portion of credit facility		0.15%
Minimum [Member] | Union Bank, N.A. and HSBC Bank USA [Member] | London Interbank Offered Rate (LIBOR) [Member]
Line of Credit Facility [Line Items]
Credit facility interest rate equal to reference rate plus		1.00%
Maximum [Member] | Union Bank, N.A. and HSBC Bank USA [Member]
Line of Credit Facility [Line Items]
Commitment fees percentage rate on unused portion of credit facility		0.25%
Maximum [Member] | Union Bank, N.A. and HSBC Bank USA [Member] | London Interbank Offered Rate (LIBOR) [Member]
Line of Credit Facility [Line Items]
Credit facility interest rate equal to reference rate plus		2.00%

Long-Term Debt (Schedule Of Lon

Long-Term Debt (Schedule Of Long-Term Debt) (Details) - USD ($) $ in Thousands	Sep. 30, 2015	Jun. 30, 2015
Long-Term Debt [Abstract]
Current long-term debt
Non-current long-term debt	$ 500,587	$ 300,594
Total long-term debt	$ 500,587	$ 300,594

Product Warranties (Details)

Product Warranties (Details) - USD ($) $ in Thousands	3 Months Ended
	Sep. 30, 2015	Sep. 30, 2014
Product Warranties [Abstract]
Balance at the beginning of the period	$ 9,823	$ 11,798
Warranty accruals for the period	1,790	3,376
Warranty costs incurred for the period	(2,039)	(1,567)
Foreign currency translation adjustments	(691)	(714)
Balance at the end of the period	$ 8,883	$ 12,893

Stock-Based Employee Compensa44

Stock-Based Employee Compensation (Schedule Of Assumptions For Fair Value Of Stock Option Plans And Purchase Rights Granted) (Details) - $ / shares	3 Months Ended
	Sep. 30, 2015	Sep. 30, 2014
Stock Options [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Weighted average grant date fair value
Weighted average risk-free interest rate
Expected option life in years	0 months	0 months
Dividend yield
Expected volatility, minimum
ESPP Purchase Rights [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Weighted average risk-free interest rate	0.10%	0.10%
Expected option life in years	6 months	6 months
Dividend yield	1.73%	2.00%
Expected volatility, minimum	26.00%	24.00%

Stockholders' Equity (Narrative

Stockholders' Equity (Narrative) (Details)	3 Months Ended
	Sep. 30, 2015USD ($)$ / sharesshares	Sep. 30, 2014USD ($)shares	Jun. 30, 2015USD ($)$ / sharesshares	Apr. 30, 1997$ / sharesshares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Cost of common shares repurchased | $	$ 62,000,000	$ 42,900,000
Common shares repurchased	1,200,000	800,000
Additional shares that can be repurchased under the approved share repurchase program	14,300,000
Number of shares repurchased pursuant to the repurchase program	40,386,234		39,186,234
Cost of shares repurchased pursuant to the repurchase program | $	$ 1,506,542,000		$ 1,444,554,000
Preferred stock, shares authorized	2,000,000		2,000,000	2,000,000
Preferred stock at par value | $ / shares	$ 0.01		$ 0.01	$ 0.01
Preferred stock, shares issued	0		0
Preferred stock, shares outstanding	0		0
Stock option and restricted stock units expiration period	7 years
Common stock authorized for issuance	43,700,000
Number of securities remaining available for future issuance	13,800,000
Reduction in the number of shares of common stock available for issuance	2.8
Maximum number of shares subject to awards granted	3,000,000
Number of common stock shares granted in participant's initial year of hiring	4,500,000
Unrecognized compensation costs related to unvested stock-based compensation arrangements | $	$ 57,100,000
Expected weighted average period of unrecognized compensation costs related to unvested stock-based compensation arrangements	2 years
Aggregate intrinsic value of the stock-based compensation arrangements outstanding | $	$ 168,500,000
Aggregate intrinsic value of the stock-based compensation arrangements exercisable | $	46,300,000
Aggregate intrinsic value of the options exercised | $	$ 8,900,000	$ 9,700,000
Employee Stock Purchase Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of securities remaining available for future issuance	1,500,000
Percentage of purchase price of common stock lower than the fair market value of common stock on the date of grant	85.00%
Percentage of purchase price of common stock lower than the fair market value of common stock on the date of purchase	85.00%
Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock options and restricted stock units vesting period	1 year
Minimum [Member] | Employee Stock Purchase Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Employee stock purchase program offering period	3 months
Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock options and restricted stock units vesting period	4 years
Maximum [Member] | Employee Stock Purchase Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Employee stock purchase program offering period	27 months
Common stock shares subscribed | $	$ 25,000

Stockholders' Equity (Schedule

Stockholders' Equity (Schedule Of Option Activity) (Details) - $ / shares	3 Months Ended	12 Months Ended
	Sep. 30, 2015	Jun. 30, 2015
Stockholders' Equity [Abstract]
Options, Outstanding at beginning of period	2,809,238
Options, Granted
Options, Exercised	(250,688)
Options, Forfeited	(12,546)
Options, Outstanding at end of period	2,546,004	2,809,238
Options, Exercise price of granted options
Options exercisable at end of period	1,987,218
Weighted Average Exercise Price, Outstanding at beginning of period	$ 29.63
Weighted Average Exercise Price, Granted
Weighted Average Exercise Price, Exercised	$ 18.34
Weighted Average Exercise Price, Forfeited	44.32
Weighted Average Exercise Price, Outstanding at end of period	30.65	$ 29.63
Weighted Average Exercise Price, Options exercisable at end of period	$ 27.67
Weighted Average Remaining Term to Vest in Years, Outstanding	2 years 6 months	2 years 6 months

Stockholders' Equity (Schedul47

Stockholders' Equity (Schedule Of Activity Of Restricted Stock Units) (Details) - Restricted Stock Units (RSUs) [Member] - $ / shares	3 Months Ended	12 Months Ended
	Sep. 30, 2015	Jun. 30, 2015
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Restricted Stock Units, Outstanding at beginning of period	2,312,529
Restricted Stock Units, Granted	7,477
Restricted Stock Units, Vested	(25,245)
Restricted Stock Units, Forfeited	(5,839)
Restricted Stock Units, Outstanding at end of period	2,288,922	2,312,529
Weighted Average Grant-Date Fair Value, Outstanding at beginning of period	$ 43.65
Weighted Average Grant-Date Fair Value, Granted	51.49
Weighted Average Grant-Date Fair Value, Vested	31.30
Weighted Average Grant-Date Fair Value, Forfeited	44.90
Weighted Average Grant-Date Fair Value, Outstanding at end of period	$ 43.81	$ 43.65
Weighted Average Remaining Contractual Term in Years, Outstanding	10 months 24 days	1 year 2 months 12 days

Fair Value Measurements (Summar

Fair Value Measurements (Summary Of Financial Assets And Liabilities) (Details) - USD ($) $ in Thousands	Sep. 30, 2015	Jun. 30, 2015
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Foreign currency hedging instruments, net	$ 1,664	$ 1,038
Business acquisition contingent consideration	$ (1,514)	$ (1,584)
Level 1 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Foreign currency hedging instruments, net
Business acquisition contingent consideration
Level 2 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Foreign currency hedging instruments, net	$ 1,664	$ 1,038
Business acquisition contingent consideration
Level 3 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Foreign currency hedging instruments, net
Business acquisition contingent consideration	$ (1,514)	$ (1,584)

Fair Value Measurements (Reconc

Fair Value Measurements (Reconciliation For Fair Value Measurements Using Significant Unobservable Inputs) (Details) - USD ($) $ in Thousands	3 Months Ended
	Sep. 30, 2015	Sep. 30, 2014
Fair Value Measurements [Abstract]
Balance at the beginning of the period	$ (1,584)	$ (480)
Acquisition date fair value of contingent consideration		(905)
Changes in fair value included in operating income		132
Payments		458
Foreign currency translation adjustments	70	(80)
Balance at the end of the period	$ (1,514)	$ (875)

Legal Actions And Contingenci50

Legal Actions And Contingencies (Details) - Contingent Obligations Under Recourse Provisions [Member] - USD ($) $ in Millions	3 Months Ended
	Sep. 30, 2015	Sep. 30, 2014	Jun. 30, 2015
Loss Contingencies [Line Items]
Receivables sold to leasing companies under debt factoring arrangements	$ 16.1	$ 2
Recourse liability recognized	0.5		$ 0.5
Maximum potential contingent liability	$ 9.1		$ 7.2

Derivative Instruments And He51

Derivative Instruments And Hedging Activities (Narrative) (Details) - USD ($) $ in Millions	3 Months Ended
	Sep. 30, 2015	Jun. 30, 2015
Derivative [Line Items]
Notional amount of foreign currency hedging contracts held	$ 620.2	$ 576.5
Foreign Currency Contracts [Member]
Derivative [Line Items]
Terms of foreign currency hedging contracts, maximum	3 years

Derivative Instruments And He52

Derivative Instruments And Hedging Activities (Summary Of Amount And Location Of Derivative Financial Instruments) (Details) - Foreign Currency Contracts [Member] - USD ($) $ in Thousands	Sep. 30, 2015	Jun. 30, 2015
Derivatives, Fair Value [Line Items]
Net foreign currency hedging instruments	$ 1,664	$ 1,038
Other Current Assets [Member]
Derivatives, Fair Value [Line Items]
Foreign currency hedging instruments, assets	3,684	1,644
Other Noncurrent Assets [Member]
Derivatives, Fair Value [Line Items]
Foreign currency hedging instruments, assets	1,574	1,348
Accrued Expenses [Member]
Derivatives, Fair Value [Line Items]
Foreign currency hedging instruments, liabilities	(790)	$ (1,954)
Other Long-Term Liabilities [Member]
Derivatives, Fair Value [Line Items]
Foreign currency hedging instruments, liabilities	$ (2,804)

Derivative Instruments And He53

Derivative Instruments And Hedging Activities (Summary Of Gains (Losses) Associated With Derivative Financial Instruments) (Details) - Derivatives Not Designated As Hedging Instruments [Member] - USD ($) $ in Thousands	3 Months Ended
	Sep. 30, 2015	Sep. 30, 2014
Derivative Instruments, Gain (Loss) [Line Items]
Gain (loss) recognized in income	$ (2,272)	$ 1,094
Foreign Currency Contracts [Member] | Other, Net [Member]
Derivative Instruments, Gain (Loss) [Line Items]
Foreign currency-hedging instruments	(39,353)	(11,054)
Other Foreign-Currency-Denominated Transactions [Member] | Other, Net [Member]
Derivative Instruments, Gain (Loss) [Line Items]
Other foreign-currency-denominated transactions	$ 37,081	$ 12,148

Subsequent Events (Details)

Subsequent Events (Details)	Oct. 02, 2015
Subsequent Event [Member] | Curative Medical Technology Inc [Member]
Subsequent Event [Line Items]
Percentage of outstanding shares acquired	100.00%